Spots Global Cancer Trial Database for Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Official Title: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Study ID: NCT05245500

Conditions

Mesothelioma

Non Small Cell Lung Cancer

Malignant Peripheral Nerve Sheath Tumors

Solid Tumor

Pancreatic Adenocarcinoma

Advanced Solid Tumor

Interventions

MRTX1719

Study Description

Brief Summary: This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Detailed Description: This first-in-human clinical trial will begin with an exploration of MRTX1719 dose and regimen. As potentially viable regimens are identified, Phase 1b expansion cohorts may be implemented to ensure sufficient safety experience, PK information, compare food effect and relative bioavailability between capsules and tablets, and early evidence of clinical activity are available to recommend Phase 2 regimens. In Phase 2, separate cohorts of patients by histological diagnosis and/or baseline characteristics will be evaluated for the clinical activity and efficacy of MRTX1719.